Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCLA Health

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1099
Shown on this page
12
Current sort
Recently updated
Campus scope
UCLA Health, Los Angeles, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCLA Health, Los Angeles, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 781–792 of 1,099 matching trials with a site at UCLA Health, Los Angeles, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028
Site status not listed — check the official record
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
Interventions
ABBV-525
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Los Angeles, California • New Haven, Connecticut • Miami Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Recruiting Phase 4 Interventional

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

NCT05208190
Status at this site: Recruiting
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Clozapine, treatment as usual
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Firearm-Safety Counseling: Medical Student Training

NCT05242627
Site status not listed — check the official record
View directory record Official record
Conditions
Medical Student Firearm Epidemiology Knowledge, Medical Student Firearm Safety Knowledge, Medical Student Initiated Clinical Firearm Safety Counseling
Interventions
Clinical Firearm Safety Counseling Module
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Recruiting Phase 1Phase 2 Interventional

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

NCT07357519
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed / Refractory Osteosarcoma
Interventions
LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
12 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Recruiting Phase 2 Interventional

Motivation for IV Alcohol Self-Administration in Humans

NCT06494891
Status at this site: Recruiting
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Intravenous Alcohol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Recruiting Phase 2 Interventional

Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke

NCT06440707
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS), Sham tDCS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734
Site status not listed — check the official record
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Physician's Choice medications
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Recruiting Phase 3 Interventional

Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.

NCT07226089
Status at this site: Not yet recruiting
View directory record Official record
Conditions
ISS, SGA
Interventions
Somatrogon, Genotropin
Drug
Lead sponsor
Rabin Medical Center
Other
Eligibility
3 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Los Angeles, California • Centennial, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Recruiting Not applicable Interventional

Optimizing Proton Pump Inhibitors (PPI) Prescribing With EHR-Based Decision Support

NCT06998966
Status at this site: Recruiting
View directory record Official record
Conditions
Prescribing Patterns, Physician, Physician's Practice Patterns, Drug Utilization Review
Interventions
Algorithmic Defaulting (Indication-Based Default), Active Physician Choice
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Recruiting Phase 2 Interventional

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCT05778591
Status at this site: Recruiting
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Buprenorphine 0.15 MG [Belbuca]
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Active, not recruiting Phase 2 Interventional Results available

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

NCT03964727
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Solid Tumor
Interventions
Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
31
States / cities
Anchorage, Alaska • Glendale, Arizona • Goodyear, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 5, 2026, 6:40 PM EST
Recruiting No phase listed Observational

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

NCT06623890
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
16 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 5, 2026, 6:40 PM EST

About this UCLA Health institution page

What this page lists
ClinicalTrials.gov records that list UCLA Health in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.